Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.357: 3alpha-hydroxysteroid 3-dehydrogenase

This is an abbreviated version!
For detailed information about 3alpha-hydroxysteroid 3-dehydrogenase, go to the full flat file.

Word Map on EC 1.1.1.357

Reaction

a 3alpha-hydroxysteroid
+
NAD(P)+
=
a 3-oxosteroid
 +
NAD(P)H
 +
H+

Synonyms

17beta-HSD5, 3-alpha hydroxysteroid dehydrogenase type 3, 3-alpha-HSD type 2, 3-alpha-HSD1, 3-alpha-hydroxysteroid dehydrogenase type 2, 3-alpha-hydroxysteroid dehydrogenase type I, 3alpha-HSD, 3alpha-HSD type III, 3alpha-HSD/CR, 3alpha-HSD3, 3alpha-HSOR, 3alpha-hydroxysteroid dehydrogenase, 3alpha-hydroxysteroid dehydrogenase type 3, 3alpha-hydroxysteroid dehydrogenase type III, 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase, 3alpha-hydroxysteroid oxidoreductase, AKR1C1, AKR1C14, AKR1C2, AKR1C3, AKR1C33, AKR1C4, AKR1C9, aldo-keto reductase family 1 member C1, aldo-keto reductase family 1 member C2, aldo-keto reductase family 1 member C3, bile acid binding protein, chlordecone reductase, DD2, DD4, dihydrodiol dehydrogenase, dihydrodiol dehydrogenase 4, dihydrodiol/3alpha-hydroxysteroid dehydrogenase, HSD 28, HSD 29, hsdA, More, NADPH-dependent AKR1C9, Naloxone reductase 2, Ps3alphaHSD, type 1 3alpha-HSD, type 3 3alpha-hydroxysteroid dehydrogenase, type 5 17beta-hydroxysteroid dehydrogenase, type I 3alpha-HSD, type III 3-alpha-hydroxysteroid dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.357 3alpha-hydroxysteroid 3-dehydrogenase

Disease

topprint

Disease on EC 1.1.1.357 - 3alpha-hydroxysteroid 3-dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Alzheimer Disease
Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer's disease.
Carcinoma
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Small Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Cholestasis
Intestinal barrier integrity and function in infants with cholestasis.
Choriocarcinoma
AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Colitis, Ulcerative
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.
Colonic Neoplasms
The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer.
Crohn Disease
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.
Fatty Liver
Effects of sanshoamides and capsaicinoids on plasma and liver lipid metabolism in hyperlipidemic rats.
Hyperandrogenism
DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome.
Hypercholesterolemia
The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: Bile salts as ligands for nuclear hormone receptors.
Neoplasms
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome.
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Neuroendocrine Tumors
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Prostatic Neoplasms
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Consecutive Prostate Cancer Specimens Revealed Increased Aldo?Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Urinary Bladder Neoplasms
Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.
Uterine Cervical Neoplasms
Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.